We are experiencing intermittent navigation issues with our website. Some of our navigation options are not appearing correctly. We are working to restore the situation quickly. Thank you for understanding.

We are experiencing intermittent navigation issues with our website. Some of our navigation options are not appearing correctly. We are working to restore the situation quickly. Thank you for understanding.
Logo - Business Development Bank of Canada - BDC
GeminX logo
Exited company

GeminX

Details
Region
Quebec
Industry sector
Biotechnology
Investment year
2001
Fund
Healthcare Venture Fund
Learn more
Lead
Ela Borenstein - Vice president, venture capital at BDC
Ela Borenstein

Vice President

View profile
About the company

Gemin X specialized in the discovery and development of novel therapeutics that modulate apoptosis, the body's natural ability to destroy diseased or damaged cells, in life-threatening diseases. The company is also applying its apoptotic platforms to develop additional products. Apoptosis is an important and normal biological process that plays a vital role in the physiological maintenance of a variety of tissues in the body.

Cephalon acquired Gemin X.